Loading
Cencora, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 24 Jun 2026.
Cencora, Inc.: what insiders have been doing
Cencora, Inc., classified in the Healthcare & Pharma sector, is a listed company based in Chesterbrook, United States, founded in 2001. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Cencora, Inc. logged 68 filings by 21 insiders.
Open-market activity splits into 3 purchases totalling €917k and 8 sales totalling €8.2M; 2 insiders sit on the buying side and 5 insiders on the selling side. The amount is not disclosed for 2 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €3.1M, sold by Campbell Elizabeth S and made public on 25 August 2026 (0.22% of market cap). The buyers include 2 senior executives.
The latest purchase dates back some time: it was published 116 days ago, on 24 June 2026. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
With 68 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. Since 2016, the database holds 4 purchases and 59 sales by insiders of the company. The 10-K for the year ended 30 September 2025 shows 321.33 bn USD of revenue and 1.55 bn USD of net income and a dividend of 2.20 USD per share.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
392
Thresholds
n/a
Buy Volume
€1M
4 ops. · all time
Sell Volume
€7B
59 ops. · all time
Who traded when
BuySaleLazarus Krikorian5 sales
Mauch Robert P.5 sales
Battaglia Silvana4 sales
Elizabeth S. Campbell4 sales
Collis Steven H2 sales
Dermot Mark Durcan2 buys
+3 other insiders
Since the insiders bought
- +18.8%Entry US$286.95 · Close 16 Oct 2026 US$340.92
- +21.3%Entry US$281.10 · Close 16 Oct 2026 US$340.92
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Cencora, Inc. Buy (bullish), based on 12 analysts. Average price target: US$367.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 14,670 of 24,161 companies
45.0
score / 100
Value45
Quality45
FCF yld4.9%
Earn yld2.4%
EV/EBITDA19.4x
ROE97%
Gross mgn3.6%
Net mgn0.5%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended September 2025 · cache
US$340.92
Analyst consensus
12 analystsBuy
US$330.00Target US$367.67(+8%)US$400.00
Income statement
RevenueUS$321.3B
Gross profitUS$11.5B4% margin
EBITDAUS$3.7B1% margin
Net incomeUS$1.6B0.8% margin
Valuation
PER (trailing)25.3x
PER (forward)17.3x
P/Book21.3x
Beta0.58
Balance sheet & cash
Market capUS$65.1B
Total debtUS$7.7B
Free Cash FlowUS$3.2B
Debt / Equity447%
Profitability & ownership
ROE96.9%
ROA3.6%
% insiders4.3%
% institutions99.4%
Last declaration on 5 October 2026
Declarations392 total
275 sharesCommon StockSEC:0001216931-26-000012:0
986 shares@ US$303.180.0005% mcap7.6% of flowCommon StockSEC:0001627534-26-000006:0
1,280 shares@ US$321.300.025% mcap23.1% of flowCommon StockSEC:0001234234-26-000004:0
1,280 shares@ US$321.31410.025% mcap100.0% of flowCommonSEC144:0001628280-26-062161
1,324 shares@ US$325.000.026% mcap6.5% of flowCommonSEC144:0001959173-26-006883
10,000 shares@ US$335.16560.20% mcap16.6% of flowCommonSEC144:0001959173-26-006742
11,300.471 shares@ US$324.1160.22% mcap30.5% of flowCommon StockSEC:0001882641-26-000008:0
11,301 shares@ US$324.10070.22% mcap30.5% of flowCommonSEC144:0001959173-26-006372
20,000 shares@ US$316.65480.38% mcap31.6% of flowCommonSEC144:0001959173-26-005708
97 shares@ US$311.340.0018% mcap11.7% of flowCommon StockSEC:0001765744-26-000008:0
97 shares@ US$311.340.0018% mcap55.9% of flowCommon StockSEC:0001555614-26-000008:0
113 shares@ US$311.340.0021% mcap9.3% of flowCommon StockSEC:0001685596-26-000006:0
58.204 shares@ US$240.5330.0009% mcap0.2% of flowCommon StockSEC:0001774724-26-000006:0
49.889 shares@ US$240.5330.0007% mcap0.1% of flowCommon StockSEC:0001882641-26-000006:0
550 sharesCommon StockSEC:0001765744-26-000006:0
Canonical exit: 20 Sept 2026 (T+90)
4,000 sharesCommon StockSEC:0001202358-26-000006:0
Canonical exit: 16 Sept 2026 (T+90)
4,000 shares@ US$266.260.046% mcap70.7% of flowCommon StockSEC:0001202358-26-000004:0
Canonical exit: 26 Aug 2026 (T+90)
8,415 shares0Common StockSEC:0001774724-26-000004:0
12,623 shares0Common StockSEC:0001882641-26-000004:0
12,623 shares0Common StockSEC:0001333281-26-000002:0
557 shares@ US$359.2847.6% of flowCommon StockSEC:0001986505-26-000002:0
557 shares@ US$359.28100.0% of flowCommon StockSEC:0001891346-26-000002:0
84 shares@ US$359.2211.2% of flowCommon StockSEC:0001765744-26-000002:0
557 shares@ US$359.2868.5% of flowCommon StockSEC:0001763963-26-000004:0
98 shares@ US$359.229.0% of flowCommon StockSEC:0001685596-26-000002:0
25 of 392 declarations
About Cencora, Inc.
Cencora, Inc. (NYSE: COR) is a major healthcare infrastructure and pharmaceutical distribution company based in Conshohocken, Pennsylvania, United States. Formerly known as AmerisourceBergen, the company rebranded as Cencora to better reflect its expanding global footprint and its central role in improving access to medicines across the healthcare supply chain. For international equity investors, Cencora is best understood not as a traditional drug manufacturer, but as a critical intermediary and service platform connecting pharmaceutical manufacturers, healthcare providers, pharmacies, and specialty practices. ([investor.cencora.com](https://investor.cencora.com/news/news-details/2023/AmerisourceBergen-becomes-Cencora-in-alignment-with-the-companys-growing-global-footprint-and-central-role-in-pharmaceutical-access-and-care/default.aspx?utm_source=openai))
The company reports two principal segments: U.S. Healthcare Solutions and International Healthcare Solutions, with certain businesses grouped in Other. Its core business remains wholesale pharmaceutical distribution, but Cencora has steadily expanded into higher-value services that support the commercialization and delivery of complex therapies. These include specialty distribution, patient and provider support services, logistics integration, data and analytics, and services for physician practices and care networks. This mix gives Cencora exposure to faster-growing areas of healthcare, particularly specialty care, oncology, ophthalmology, and advanced therapies. ([investor.cencora.com](https://investor.cencora.com/news/news-details/2026/Cencora-Reports-Fiscal-2026-First-Quarter-Results/default.aspx?utm_source=openai))
Read moreShow less
In competitive terms, Cencora holds a strong scale position in U.S. pharmaceutical distribution, an industry defined by high regulatory, logistical, and technology barriers. The company emphasizes its ability to improve product access, traceability, inventory resilience, and supply-chain efficiency. At the same time, management is actively broadening the platform through targeted investments in specialty healthcare. In 2025, Cencora completed the acquisition of Retina Consultants of America (RCA), strengthening its specialty management services platform. The company also announced plans to invest about $1 billion through 2030 to expand and harden its U.S. distribution network, including added capacity and improved resilience. ([cencora.com](https://www.cencora.com/newsroom/cencora-advances-specialty-leadership-through-acquisition-of-retina-consultants-of-america?utm_source=openai))
Recent developments underline this strategy. In 2025, Cencora reported growth in revenue and adjusted earnings, supported by underlying market expansion and acquisition-driven contributions. In 2026, the company announced acceleration of its OneOncology investment and a transaction involving MWI Animal Health and Covetrus, further reinforcing its specialty and animal-health platforms. Taken together, these moves point to a company pursuing a balanced strategy: defend its scale leadership in pharmaceutical distribution while building a broader, higher-margin services ecosystem around specialty care. For long-term investors, that combination offers a defensive healthcare profile with structural growth opportunities tied to the complexity of modern care delivery. ([investor.cencora.com](https://investor.cencora.com/news/news-details/2025/Cencora-Accelerates-OneOncology-Acquisition-Extending-Solutions-Offering-for-Community-Oncology/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
